Register to attend a free NIH webinar. Attendees will learn about a new adjuvanted subunit mucosal COVID-19 vaccine. Study results show this new vaccine prevents SARS-CoV-2 transmission and infection. Most SARS-CoV-2 vaccines focus on delivering immunization through an intramuscular injection. This new technology combines an initial intramuscular injection with subsequent intranasal boost administration of a novel, molecular adjuvant nanoparticle formulation.

The inventors will discuss this new intranasal vaccine formulation, the combined intramuscular prime and intranasal boost methodology, and results from applying this method for treating and preventing SARS-CoV-2 transmission and infection.

The NCI is looking for a collaboration/licensing partner to assist with further development of this technology, ultimately leading to a clinical trial and/or take on commercial development.